Republicans Open Second Front to Repeal Device Tax With Budget
This article was originally published in The Gray Sheet
While two bills are already under consideration in the current Congress to repeal a 2.3 percent medical device tax instituted as part of the Affordable Care Act, GOP lawmakers have proposed budgets that would repeal the excise tax.
You may also be interested in...
Medical Innovation Bills On Fast Track In Congress, But Some Barriers Remain
With an all-Republican House, Senate and administration lined up to lead the government following the 2016 elections, the path is clear for passage of a set of FDA reforms to ease device approvals embedded in a combined House 'Cures' and Senate medical innovation package. It could even happen over the upcoming lame-duck session, before the new administration and Congress take over. But controversy around price-gouging by drug firms still could stymie quick Cures bill passage, an industry attorney predicts. Meanwhile, medtech industry groups plan to seize on the Trump victory as a means to achieve permanent device tax repeal.
Podcast: Diversity, Equity, and Inclusion Measures Continue to Evolve in the Clinical Space
Listen to expert perspectives from Tracey Parker, Vice President, Biometrics, Advanced Clinical and Rebecca Starkie, Senior Global Patient Engagement Director, Advanced Clinical on the recent history of DEI in clinical trials and the barriers to patient participation. Examine the key drivers that have influenced the development of diversity, equity, and inclusion programs for clinical trials.
Doc On Call? Cosmetic Manufacturers May Need M.D. On Retainer Under MoCRA
Cosmetic manufacturers may need to retain a medical professional to determine if adverse events they receive are minor or serious given the looming deadline for maintaining records and reporting serious adverse events to the US FDA, says Locke Lord partner David Abramowitz.